Table 1 Patient characteristics

From: Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial

Baseline characteristic

N (%) (n = 40)

Age

  Years (median, range)

62 (32–78)

Sex

 

  Male

31 (77.5)

  Female

9 (22.5)

Race

 

  Caucasian/White

38 (95.0)

  Oriental/Asian

2 (5.0)

ECOG PS

 

  0

28 (70.0)

  1

12 (30.0)

Primary Site

 

  Rectum

20 (50.0)

  Colon

18 (45.0)

  >1 Primary site

2 (5.0)

Site of metastases

 

  Liver

34 (85.0)

  Lung

10 (25.0)

  Other

13 (32.5)

Interval between first diagnosis and metastatic disease

 

  Days (median, range)

66.5 (0–2068)

Back to article page